Drug Profile


Alternative Names: HI-113; PHI-113

Latest Information Update: 27 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Parker Hughes Institute
  • Developer Paradigm Pharmaceuticals; Parker Hughes Institute
  • Class Antiretrovirals
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Adenovirus infections; HIV-1 infections

Most Recent Events

  • 16 Feb 2006 This compound appears to still be in active development
  • 16 Oct 2003 A preclinical study has been added to the Viral Infections pharmacodynamics section
  • 20 Nov 2002 Two studies have been added to the Viral infections antimicrobial activities section and one study has been added to the adverse events and pharmacokinetics sections ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top